Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.
Press releases published on May 14, 2025
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the research and commercialization of ketamine for unmet medical needs, today …
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
GlobeNewswire
·
May 14, 2025
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology ( …
Waterfall Network Augments Web3 Tools with Cascadify and The Lamb
GlobeNewswire
·
May 14, 2025
Zug, Switzerland , May 14, 2025 (GLOBE NEWSWIRE) -- Waterfall Network, a rapidly growing BlockDAG ecosystem focused on scalability and seamless user experience, today announced the launch of Cascadify and The Lamb, two new tools designed to enhance the …
Bombardier Announces Launch of US$500 million New Issuance of Senior Notes due 2033 to retire US$500 million of its Senior Notes due 2027
GlobeNewswire
·
May 14, 2025
MONTRÉAL, May 14, 2025 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has launched an offering of US$500 million aggregate principal amount of new Senior Notes due 2033 (the “New Notes”). Bombardier intends to use the proceeds …
Bombardier annonce le lancement d'une nouvelle émission de 500 millions $ US de billets de premier rang échéant en 2033 pour rembourser 500 millions $ US de ses billets de premier rang échéant en 2027
GlobeNewswire
·
May 14, 2025
MONTRÉAL, 14 mai 2025 (GLOBE NEWSWIRE) -- Bombardier Inc. (« Bombardier ») a annoncé aujourd’hui qu’elle avait lancé un placement de nouveaux billets de premier rang échéant en 2033 d’un montant en capital global de 500 millions $ US (les « nouveaux …
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive …
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)
GlobeNewswire
·
May 14, 2025
Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncology …
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the …
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
GlobeNewswire
·
May 14, 2025
Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to Baseline Key endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index ( …
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
GlobeNewswire
·
May 14, 2025
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., May 14, 2025 (GLOBE …
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire
·
May 14, 2025
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann …
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
GlobeNewswire
·
May 14, 2025
CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …
nCino Announces Timing of its First Quarter Fiscal Year 2026 Financial Results Conference Call
GlobeNewswire
·
May 14, 2025
WILMINGTON, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, will report financial results for its first quarter ended April 30, 2025, after the market close on …
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports interim data readout expected in the second half of …
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
GlobeNewswire
·
May 14, 2025
Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operations Enrollment in LAVA-1266 Phase 1 continues to progress Cash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 …
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of …
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 14, 2025
- Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first …
[Latest] Global Pharmaceutical Container Market Size/Share Worth USD 189.45 Billion by 2034 at a 6.98% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
GlobeNewswire
·
May 14, 2025
Austin, TX, USA, May 14, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pharmaceutical Container Market Size, Trends and Insights By Product Type (Bottles, Vials …
Peter Lambrinakos, O.O.M., CPP, Joins Draganfly’s Public Safety Advisory Board, Strengthening Canadian Leadership in Public Safety
GlobeNewswire
·
May 14, 2025
Veteran leader in public safety, national security, and critical infrastructure protection brings strategic, operational, and innovation expertise to advance Draganfly’s public safety mission Saskatoon, SK, May 14, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. ( …
Calian annonce les résultats du deuxième trimestre
GlobeNewswire
·
May 14, 2025
(Tous les montants dans le communiqué sont en dollars canadiens.) OTTAWA, Ontario, 14 mai 2025 (GLOBE NEWSWIRE) -- CalianMD Group Ltd. (TSX : CGY), une société qui fournit des solutions essentielles à la mission, axée sur la défense, l’espace, les soins de …